The Meeting will be held in Bali on October 29-31, providing a platform for manufacturers from developing countries to share experiences, showcase achievements, and strengthen partnerships for a resilient vaccine ecosystem.
"Through this meeting, we aim to demonstrate Indonesia’s tangible contribution to advancing global vaccine self-reliance," Bio Farma President Director Shadiq Akasya said in a statement on Monday.
Bio Farma is Indonesia’s state-owned life science company and the largest vaccine manufacturer in Southeast Asia.
Shadiq highlighted the AGM’s strategic role in fostering collaboration.
"Through knowledge exchange, capacity building, and technological innovation, manufacturers from developing countries can lead in building equitable global health resilience,” he added.
The AGM, themed "Advancing innovation and building a resilient vaccine ecosystem for a safer world", will gather vaccine manufacturers, health institutions, and their partners to discuss innovation, scientific progress, and sustainable vaccine supply strategies.
Sessions of AGM will cover the 2025 economic outlook, public health financing, vaccine affordability, regulatory strategies for low- and middle-income countries, and Africa-focused initiatives, such as unified procurement and sustainable pricing.
DCVMN CEO Rajinder Suri emphasized the importance of translating innovation into vaccines that are developed, manufactured, and delivered where it needed most.
He also highlighted on connecting real-world experiences with regulatory strategies and partnerships to ensure vaccine timely access.
“Advancing innovation and building resilient vaccine ecosystems is not an abstract ambition. It is a practical imperative!" he stated.
In 2025, DCVMN facilitated over 150 meetings with international partners while its Working Groups produced peer-reviewed publications, e-learning modules, technical analyses, and position papers. In the 2015-2021 period, the network enabled over 115 South-to-South collaborations.
Furthermore, the AGM will also discuss the operation of Pandemic Agreement and Pandemic Fund to ensure inclusive support for vaccine manufacturers from developing countries.
Founded in 2000, DCVMN gathers 46 vaccine manufacturers from 17 developing countries and collaborates with WHO, UNICEF, Gavi, CEPI, PATH, CHAI, and the Gates Foundation to ensure equitable access to high-quality vaccines worldwide.
Related news: Bio Farma strengthens global vaccine development through DCVMN
Related news: Bio Farma's participation in DCVMN contributes to global health
Reporter: Martha Herlinawati Simanjuntak
Editor: Yuni Arisandy Sinaga
Copyright © ANTARA 2025
